Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>Shares of Supriya Lifescience listed at ₹425 while the price band was fixed at ₹265-274 per share.</li><li>The IPO was a hit among investors as it has been subscribed just 73.94 times on the last day of the bidding.</li><li>The market capitalisation of the company stood at ₹3,420 crore.</li></ul>The Mumbai-based active pharmaceutical ingredients (APIs) manufacturer, Supriya Lifescience made a strong debut on the National Stock Exchange (NSE) and BSE. The stock listed at ₹425, which is 55.11% more than the issue price band of ₹265-274 apiece. The listing gains of Supriya Lifescience met investors expectations of 40-50% premium led by high grey market premium, positive recommendation by analysts as the company is backed by strong financials with attractive valuations. “Supriya Lifesciences, another good company from the API segment garnered lots of investors' interest on the back of strong financials and attractive valuations. We are expecting a strong listing of this company as market sentiments have improved and the IPO witnessed strong subscription numbers. The grey market is indicating a listing gain of more than 50%,” said Aayush Agrawal, senior analyst at Swastika Investmart. <div type="image" title="surpriya rev" height="900" width="1200" msid="88536223" hostid="261"></div> Post listing, the market capitalisation of the company stood at ₹3,420 crore, according to BSE data. The company raised ₹700 crore through the IPO, which consists of a fresh issue of ₹200 crore and an offer for sale of ₹500 crore. The net proceeds from the fresh issue will be utilised towards capital expenditure requirements, repaying of debts, and general corporate purposes. The shares of Supriya Lifescience were trading at ₹xx, lower by x% at 10.00 a.m., on December 28. The grey market had also indicated a good listing as unlisted shares of Supriya Lifescience were commanding a marginal premium of ₹140 per share. The IPO, which was open between December 16 and December 20, received strong response from investors. It was subscribed 73.94 times on the last day of the bidding. The company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Supriya Lifescience products have been exported to 86 countries and 1,296 customers in FY21. The company has API business in Europe, Latin America, Asia, and North America. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/cms-info-systems-ipo-heres-how-to-check-your-allotment-status/articleshow/88532050.cms">CMS Info Systems IPO: Here’s how you can check the allotment status</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/startups/news/2021-indias-year-of-the-unicorn-and-its-many-high-points/slidelist/88528773.cms">India’s year of the unicorn and its many high point</a>

Supriya Lifescience beats IPO investors expectations and debuts with 55% premium

Supriya Lifescience, Paras Defence, Indian Hotels, ONGC, and other hot stocks to watch on December 28

<ul><li>Supriya Lifescience is likely to announce its share allotment status today.</li><li>Mumbai-based active pharmaceutical ingredients (APIs) manufacturer Supriya Lifescience’ IPO was subscribed 73.94 times.</li><li>The IPO will be listed on December 28 on exchanges.</li></ul>The Mumbai-based active pharmaceuticals ingredients (APIs) manufacturer, Supriya Lifescience, is likely to announce the allotment status of its initial public offering (IPO) today, December 23. The IPO was open for subscription from December 16 to December 20. The company received bids for ₹103 crore as against ₹305 crore worth shares on offer. <keyword id="11265715" type="General" weightage="20" keywordseo="supriya-lifescience-ipo" source="Orion">Supriya Lifescience IPO</keyword> received great demand from investors as its IPO was subscribed for 73.94 times the number of shares offered in the three days of IPO bidding process. Moreover, the grey market premium of the company’s shares show a premium of ₹130 from the higher end of the price band. The portion reserved for retail investors was oversubscribed by 57.91 times on the last day of the IPO bidding process. The company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Here is how to <keyword id="12794349" type="General" weightage="20" keywordseo="supriya-lifescience-ipo-allotment" source="Orion">Supriya Lifescience IPO allotment</keyword> status on stock exchange website: <ul><li>Go to the <a href="https://www.bseindia.com/investors/appli_check.aspx">BSE website</a> or NSE website<a href="https://www1.nseindia.com/products/dynaContent/equities/ipos/ipo_login.jsp"> here</a>.</li><li>On BSE, Select 'Equity' and then from the dropdown, select ‘Supriya Lifescience’.</li><li>Now, enter your application number and PAN.</li><li>Click on 'Search'.</li><li>Please note the details will only be available once the shares are allotted.</li></ul>You can also visit the registrar website (Link Intime India) to check your application status. <ul><li>Visit the registrar's website <a href="https://linkintime.co.in/MIPO/Ipoallotment.html">here</a>.</li><li>Click on 'Select company' and click on ‘Supriya Lifescience’.</li><li>Once the company is selected, you will have to enter either your PAN detail, the application number, or the client ID.</li><li>Enter the captcha and click ’submit’.</li></ul>Once you hit 'submit', the status of your application will appear on the screen. Please ensure the details that you provide are correct. It will show the number of shares you subscribed to and the number of shares allotted to you. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/corporates/news/the-zee-plus-sony-company-is-valued-at-300-a-share-but-thats-just-the-starting-point/articleshow/88432204.cms">The Zee plus Sony company is valued at ₹300 a share, but that’s just the starting point</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/not-received-data-patterns-ipo-refund-here-are-the-things-you-should-know-about/articleshow/88431930.cms">Not received Data Patterns’ IPO refund? Here are the things you should know about</a>

Supriya Lifescience IPO: Here’s how you can check the allotment status

<ul><li>Today is the first day to subscribe to the <keyword id="11265715" type="General" weightage="20" keywordseo="supriya-lifescience-ipo" source="Orion">Supriya Lifescience IPO</keyword>, which will close on December 20.</li><li>The pharmaceutical company is intending to raise ₹700 crore through the IPO, which consists of a fresh issue of ₹200 crore and offer for sale of ₹500 crore.</li><li>Shares of the company are demanding a premium of ₹250 per share in the grey market .</li><li>Analysts recommend subscribing to the issue on some positive factors — diversified product portfolio, strong foothold in international markets, valuation at a discount compared to peers.</li></ul>Amid myriad initial public offerings (IPO) going on, here is another one worth giving attention to, as analysts recommend subscribing to this one on its good fundamentals. Today is the first day to subscribe to the initial public offering (IPO) of Mumbai-based active pharmaceutical ingredients (APIs) manufacturer, Supriya Lifescience. The company produces 38 active pharmaceutical ingredients (APIs) focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company’s manufacturing facility is in Parshuram Lote, about 250 kilometres away from Mumbai, Maharashtra. Supriya Lifescience is looking to raise ₹700 crore through the IPO, which consists of a fresh issue of ₹200 crore and an offer for sale of ₹500 crore. Most analysts are positive and suggest subscribing to the issue because of its diversified product range, strong foothold in international markets and valuation at discount compared to peers. Adding to it, shares of the company are demanding a premium of ₹250 per share in the grey market . <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;" class="redcator-table-advance"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Brokerages </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Recommendation </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Angel One </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Choice Broking </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">BP Equities </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Investmentz </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe for long term </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Religare Broking </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Positive view on a long term </td></tr></tbody><tbody></tbody><tbody></tbody><tbody></tbody><tbody></tbody><tbody></tbody><tbody></tbody></table> Supriya Lifescience’s products have been exported to 86 countries and 1,296 customers in FY21. The company has API business in Europe, Latin America, Asia, and North America. Its products are registered with various international regulatory authorities including the US, Europe and China. “Supriya Lifescience has de-risked its business model with wide geographical presence, diversified product portfolio, catering to diverse therapeutic areas. Also the company has demonstrated a healthy profitable business growth with stable operating cash flows. Since inception, it has reported a positive operating cash flow,” said analysts at Choice Broking while assigning a “SUBSCRIBE” rating for the issue given the valuation is at discount to the peer average. Analysts from stock broking firm Investmentz say that with the company’s superior product mix, established brand name, strong relationships with leading global companies, and adding capacities, “we believe the company is well placed to capitalise on domestic and global opportunities”. Considering the company’s niche product portfolio and strong geographical presence, its valuation seems attractive to analysts. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;" class="redcator-table-advance"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Peer company </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Revenue for FY21 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Stock price </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">% returns in 2021 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Solara Active Pharma Sciences </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹1,645 crore </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹1,088 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-7.9% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Neuland Laboratories </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹953 crore </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹1,591 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">45% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Aarti Drugs </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹2,159 crore </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹984 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-24% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Wanbury </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹394.9 crore </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹83 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">77% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Divi’s Laboratories </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹7,032 crore </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹4,586 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">19% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Supriya Lifescience </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹396 crore </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹265 - ₹274 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">- </td></tr></tbody><tbody></tbody><tbody></tbody><tbody></tbody><tbody></tbody><tbody></tbody><tbody></tbody></table> “Supriya Lifescience focuses on research and development and having a diversified niche product portfolio of API’s. Companies 77.5% of revenue comes from the Export market, companies’ key markets are USA, Europe, China and India. We believe that the company's new manufacturing unit and product launch will be growth drivers for the company in future,” said a report by Angel One. The issue is attractively priced at the upper end of the price band, which is significantly discounted to its listed peers with similar return and margin profile explained a report by BP Equities. <div type="image" title="supriya life rev 2" height="900" width="1200" msid="88314031" hostid="261"></div> SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/retail/news/aditya-birla-fashion-will-now-sell-reebok-products-in-india-and-10-other-asian-countries/articleshow/88272443.cms">Aditya Birla Fashion will now sell Reebok products in 11 Asian countries — and it may reap benefits soon</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/news/moschip-technologies-asm-technologies-and-spel-semiconductor-among-chip-makers-stock-that-surged-on-pli-scheme/articleshow/88306809.cms">Checkout chip makers’ stocks that surged on PLI scheme; industry leaders feel the move will make India self-reliant</a>

Analysts suggest subscribing to this pharma company IPO on discounted valuation and strong product portfolio than peers

IPOs in FY23 have been fewer but many have fared better than the previous year

Nykaa, Policybazaar, Paytm among nine companies whose IPO lock-in period ends in November

<ul><li>In December, <keyword id="6357979" type="General" weightage="20" keywordseo="mutual-funds" source="Orion">mutual funds</keyword> deployed ₹14,700 crore in the secondary market.</li><li>Mutual funds participated in the IPO of five of the seven companies that debuted on the stock exchanges during December.</li><li>Key stocks that mutual funds bought in the month of December include HDFC, Reliance Industries and Maruti Suzuki.</li><li>While smallcap funds and midcap funds witnessed highest flows during December, multicap, largecap , flexicap and focused schemes were out of flavour as they either saw outflow or negligible inflows.</li><li>SIP inflows hit an all-time high of ₹13,573 crore in December. </li></ul>In December, mutual funds deployed ₹14,700 crore in the secondary market while foreign institutional investors (FIIs) sold ₹6,300 crore, says a report by Nuvama Institutional Equities (previously known as Edelweiss Institutional Equities). Mutual funds have also participated strongly in initial public offerings (IPOs) in December – investing in five of the seven initial public offers that made their debuts on the stock exchanges during the month. The fund houses deployed ₹440 crore in Kfin Technologies, ₹150 crore in Sula Vineyards, ₹120 crore in Landmark Cars, ₹100 crore in Elin Electronics and ₹20 crore in Radiant Cash Management. Inflows into equity mutual fund schemes also more than tripled to ₹7,303 crore in December, from ₹2,258 crore in November, according to Association of Mutual Funds in India (AMFI). This means that inflows into equity MFs have been positive for 22 months straight now. Key stocks that mutual funds bought in the month of December include HDFC, Reliance Industries and Maruti Suzuki while they trimmed their holdings in Axis Bank, HCL Technologies and ICICI Bank, as per Nuvama. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Key additions by MFs </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Key deductions by MFs </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">HDFC (₹2,410 crore) </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Axis Bank (₹1,330 crore) </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Reliance Industries (₹1,890 crore) </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">HCL Technologies (₹830 crore) </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Maruti Suzuki (₹1,670 crore) </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">ICICI Bank (₹570 crore) </td></tr></tbody></table>(Source: Nuvama Institutional Equities) While smallcap funds and midcap funds witnessed highest flows for the month, multicap, largecap, flexicap and focused schemes were out of flavour with these witnessing either outflows or negligible inflows. This has been the trend for quite a few months now, says Nuvama. Strong inflows in mutual funds is because of consistent commitment made by retail investors through systematic investment plans (SIPs). The number of SIP accounts in the industry reached 6.12 crore in December against 6.04 crore in November. In fact, SIP inflows are at an all-time high, hitting ₹13,573 crore in December. Meanwhile, the net assets under management (AUM) of the mutual fund industry grew to ₹39.88 lakh crore from ₹37.72 lakh crore last year. <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Key additions in Midcap by MFs </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Key reductions in Midcap by MFs </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Key additions in Smallcap by MFs </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Key reductions in Smallcap by MFs </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Ajanta Pharma </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Narayana Hrudayalaya </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Sapphire Foods </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Amara Raja Batteries </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Jindal Stainless </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Gujarat Gas </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">KFin Technologies </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Praj Industries </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Max Financial </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Ramco Cements </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">GMM Pfaudler </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Eris Lifesciences </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Power Finance Corp </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Voltas </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;"> </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;"> </td></tr></tbody></table>(Source: Nuvama Institutional Equities) SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/corporates/news/hcl-tech-lowers-revenue-guidance-for-fy23-to-13-5-14-q3-revenue-and-profit-growth-beat-expectations/articleshow/96944379.cms">HCL Tech lowers revenue guidance for FY23 to 13.5-14%, Q3 revenue and profit growth beat expectations</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/corporates/news/infosys-results-q3-fy23-infosys-raises-revenue-guidance-for-fy23-to-16-16-5/articleshow/96941824.cms">Infosys raises revenue guidance for FY23 to 16-16.5%, revenue growth beats analyst expectations</a>

MFs add HDFC, Reliance Industries, KFin Tech, Sula Vineyards in December

<ul><li><keyword id="236770" type="General" weightage="20" keywordseo="adani-wilmar" source="Orion">Adani Wilmar</keyword> is likely to announce its share allotment status today.</li><li>FMCG company Adani Wilmar’s – known for edible oil brand Fortune IPO was subscribed 18.33 times.</li><li>The IPO will be listed on February 8 on exchanges.</li></ul>The fast moving consumer goods (FMCG) company Adani Wilmar’s – known for edible oil brand Fortune, is likely to announce the allotment status of its initial public offering (IPO) today, February 3. The IPO was open for subscription from January 27 to January 31. The company received bids for 212.7 crore shares as against 11.6 crore shares on offer. In the first two days of the subscription process, the IPO received a tepid response from investors as it was oversubscribed by 1.19 times. However, on the last day, Supriya Lifescience IPO received great demand from investors as its IPO was subscribed for 18.33 times the number of shares offered. Moreover, the grey market premium of the company’s shares showed a premium of ₹40 from the higher end of the price band. Adani Wilmar is a joint venture between Adani Group and Singapore-based Wilmar, which was formed in 1999. It sells cooking oils under the Fortune brand as well as various other food products like rice and sugar. Here is how to <keyword id="11909643" type="General" weightage="20" keywordseo="adani-wilmar-ipo" source="Orion">Adani Wilmar IPO</keyword> allotment status on stock exchange website: <ul><li>Go to the <a href="https://www.bseindia.com/investors/appli_check.aspx">BSE website</a> or NSE website<a href="https://www1.nseindia.com/products/dynaContent/equities/ipos/ipo_login.jsp"> here</a>.</li><li>On BSE, Select 'Equity' and then from the dropdown, select ‘Adani Wilmar’.</li><li>Now, enter your application number and PAN.</li><li>Click on 'Search'.</li><li>Please note the details will only be available once the shares are allotted.</li></ul>You can also visit the registrar website (Link Intime India) to check your application status. <ul><li>Visit the registrar's website <a href="https://linkintime.co.in/MIPO/Ipoallotment.html">here</a>.</li><li>Click on 'Select company' and click on ‘Adani Wilmar’.</li><li>Once the company is selected, you will have to enter either your PAN detail, the application number, or the client ID.</li><li>Enter the captcha and click ’submit’.</li></ul>Once you hit 'submit', the status of your application will appear on the screen. Please ensure the details that you provide are correct. It will show the number of shares you subscribed to and the number of shares allotted to you. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/manyavars-vedant-fashions-ipo-is-heavily-expensive-for-investors-as-per-analysts/articleshow/89299258.cms">Here’s why analysts are saying Manyavar’s IPO is heavily expensive leaving very little room for investor profit</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/enterprise/news/more-employees-are-leaving-tech-mahindra-than-tcs-and-wipro/articleshow/89291721.cms">More employees are leaving Tech Mahindra than TCS and Wipro</a>

Adani Wilmar IPO: Here’s how you can check the allotment status

<ul><li><keyword id="407979" type="General" weightage="20" keywordseo="ajanta-pharma" source="Orion">Ajanta Pharma</keyword> today announced its plans to buy back 11.20 lakh shares from the market at ₹2,550 per share, which is 10% more than the current market price.</li><li>This is the third share buy back strategy of the company so far.</li><li>In 2020, the company had bought 7.35 lakh shares at ₹1,850 per share and in 2019 it had bought 7.69 lakh shares at ₹1,300.</li></ul>Shares of Ajanta Pharma surged 7% today after the company announced a share buy back of 11.20 lakh shares at ₹2,550 per share, which is nearly 17% above the previous close price of ₹2,180.30. This is the third buyback done by the company in the last three years. In 2020, the company had bought 7.35 lakh shares at ₹1,850 per share and in 2019 it had bought 7.69 lakh shares at ₹1,300. <div type="image" title="ajanta pharma sahre" height="900" width="1200" msid="88539746" hostid="261"></div> Usually, a share buy back is done to reduce the number of outstanding shares in the market and increase the shares of the stakeholders. Also, a company might also buy back shares if it believes the share price is below the intrinsic value. In Ajanta Pharma’s case, shares of the company have performed well and surged 40% in 2021. The Maharashtra-based company’s financial performance has also seen a smooth growth trajectory. The company is a specialty pharmaceutical formulation company engaged in the development, manufacture and marketing of quality finished dosages. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Particulars </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Total income </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Profit </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Jul-Sep </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹914 crore </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹195 crore </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Apr-Jun </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹780 crore </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹173 crore </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Jan-Mar </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹759 crore </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹159 crore </td></tr></tbody></table> SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/finance/banks/news/there-is-a-small-pool-of-hope-amid-all-the-fear-around-rbl-bank/articleshow/88538626.cms">There is a small pool of hope amid all the fear around RBL Bank</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/supriya-lifescience-beats-ipo-investors-expectations-and-debuts-with-55-premium/articleshow/88536233.cms">Supriya Lifescience beats IPO investors expectations and debuts with 55% premium</a>

Ajanta Pharma surges as much as 7% after the drug maker says it will buy back shares at 17% premium

Equity benchmark <keyword id="6484188" type="General" weightage="100" keywordseo="sensex" source="Orion">Sensex</keyword> jumped over 300 points in early trade on Tuesday, tracking gains in index heavyweights <keyword id="6354512" type="General" weightage="20" keywordseo="infosys" source="Orion">Infosys</keyword>, Reliance Industries and HDFC Bank amid a largely positive trend in global markets. The 30-share index surged 320.31 points or 0.56 per cent to 57,740.55 in the opening trade. Similarly, the <keyword id="6354813" type="General" weightage="80" keywordseo="nifty" source="Orion">Nifty</keyword> rose 94.70 points or 0.55 per cent to 17,180.95. <keyword id="106317" type="General" weightage="20" keywordseo="asian-paints" source="Orion">Asian Paints</keyword> was the top gainer in the Sensex pack, rising around 2 per cent, followed by Tech Mahindra, <keyword id="6354919" type="General" weightage="20" keywordseo="lt" source="Orion">L&amp;T</keyword>, Infosys, HCL Tech and PowerGrid. On the other hand, <keyword id="44587" type="General" weightage="20" keywordseo="dr-reddy" source="Orion">Dr Reddy</keyword>'s was the sole laggard. In the previous session, the 30-share equity benchmark settled 295.93 points or 0.52 per cent higher at 57,420.24, and Nifty recovered 82.50 points or 0.49 per cent to 17,086.25. Meanwhile, foreign institutional investors (FIIs) remained net sellers in the capital market, as they sold shares worth Rs 1,038.25 crore on Monday, according to stock exchange data. "If the market's ability to discount the future turns right, the global economy is likely to clock decent growth in 2022," said VK Vijayakumar, Chief Investment Strategist at Geojit Financial Services. The resilience of the US market (S&amp;P 500 registered its 69th record high yesterday) and the spike in crude are indications that the Omicron variant, though surging, is unlikely to impact economic activity in any meaningful way, he noted. Elsewhere in Asia, bourses in Shanghai and Hong Kong were trading with losses in mid-session deals, while Seoul and Tokyo were positive. Stock exchanges in the US ended with strong gains in the overnight session. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/supriya-lifescience-beats-ipo-investors-expectations-and-debuts-with-55-premium/articleshow/88536233.cms" style="">Supriya Lifescience beats IPO investors expectations and debuts with 55% premium</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/govt-panel-allows-emergency-use-of-mercks-new-drug-molnupiravir-for-treatment-of-mild-to-moderate-covid-19-cases/articleshow/88536179.cms">Govt panel allows emergency use of Merck's new drug Molnupiravir for treatment of mild-to-moderate COVID-19 cases</a>

Sensex surges 500 points; shares of Eicher Motors, L&T, Asian Paints, automobile, IT companies among top gainers

<ul><li>US <keyword id="6354298" type="DEFINITION" weightage="60" keywordseo="Stocks">stocks</keyword> retreated from record highs on Wednesday as a deadlock in stimulus negotiations continued.</li><li>The reversal came after the Dow Jones industrial average, S&amp;P 500, and Nasdaq composite all notched new intraday records in morning trades.</li><li>Senate Majority Leader Mitch McConnell slammed Democrats on Wednesday for not lining up behind a $916 billion stimulus plan that does not include additional federal unemployment benefits.</li><li><a href="https://markets.businessinsider.com/indices">Watch major indexes update live here</a>.</li></ul>US stocks hit record highs in early trading on Wednesday, but subsequently reversed lower as fiscal stimulus negotiations appeared to be deadlocked as of Wednesday afternoon.Senate Majority Leader <a href="https://www.businessinsider.com/mcconnell-trashed-democrats-delaying-unemployment-aid-gop-federal-unemployment-benefits-2020-12">Mitch McConnell blasted Democrats</a> for not lining up behind a more than $900 billion proposal that does not include additional federal unemployment benefits. The <a href="https://www.businessinsider.com/white-house-proposes-new-coronavirus-package-with-600-stimulus-checks-2020-12">stimulus package</a> would include direct checks worth $600, aid to state and local governments, and liability protections for businesses and schools. Here's where US indexes stood after the 4 p.m. ET close on Wednesday:<ul><li><a href="https://markets.businessinsider.com/index/s&amp;p_500_500" target="_blank" rel="noopener">S&amp;P 500</a>: 3,672.82, down 0.8%</li><li><a href="https://markets.businessinsider.com/index/dow_jones" target="_blank" rel="noopener">Dow Jones industrial average</a>: 30,068.81, down 0.4% (105 points)</li><li><a href="https://markets.businessinsider.com/index/nasdaq_composite" target="_blank" rel="noopener">Nasdaq composite</a>: 12,338.95, down 1.9%</li></ul>Read more: <a href="https://www.businessinsider.com/top-wall-street-investors-of-2020-stock-picks-2021-outlook-2020-12" target="_blank" rel="noopener">We spoke with Wall Street's 9 best-performing fund managers of 2020 to learn how they crushed the chaotic market - and compile the biggest bets they're making for 2021</a>House Speaker Nancy Pelosi and Senate Minority Leader Chuck Schumer called the sizable slash in unemployment benefits "unacceptable," but did note progress given that Senate Majority Leader Mitch McConnell signed off on the proposal.<a href="https://markets.businessinsider.com/news/stocks/doordash-stock-price-ipo-public-trading-debut-nyse-dash-offering-2020-12-1029878632">DoorDash made its public debut on Wednesday</a>, completing its IPO offering and surging as much as 78% in initial trades of the delivery platform company.<a href="https://markets.businessinsider.com/stocks/glsi-stock">Greenwich LifeSciences,</a> a small cap clinical stage biotech company, <a href="https://markets.businessinsider.com/news/stocks/greenwich-lifesciences-stock-price-rally-single-day-breast-cancer-data-2020-12-1029878976">rocketed as much as 2,941% in Wednesday trades</a> after the company announced encouraging data for its breast cancer treatment, GP2. Read more: <a href="https://www.businessinsider.com/tesla-stock-outlook-ron-baron-interview-bullish-spacex-elon-musk-2020-12" target="_blank" rel="noopener">Ron Baron earned a $4.2 billion windfall just from investing in Tesla. The legendary investor told us why he still expects a 30-fold return from Elon Musk - and shared the biggest lessons and mistakes of his career.</a><a href="https://markets.businessinsider.com/news/stocks/fireeye-stock-price-cybersecurity-firm-cyber-attack-hack-tools-theft-2020-12-1029877278">FireEye stock tumbled on Wednesday</a> after it revealed a highly sophisticated security breach by what it believes to be was a state-sponsored actor. <a href="https://markets.businessinsider.com/news/stocks/zoom-stock-price-downgraded-jpmorgan-covid19-vaccine-could-dent-upside-2020-12-1029877473">Zoom Video was downgraded by JPMorgan</a> to Neutral on Wednesday, citing a high valuation that prices in all potential upside, and the mass vaccination against the COVID-19 virus which could put a dent in its business.Oil prices edged higher. <a href="https://markets.businessinsider.com/commodities/oil-price?type=wti">West Texas Intermediate crude</a> rose as much as 1.4%, to $46.24 per barrel. <a href="https://markets.businessinsider.com/commodities/oil-price?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingestts&amp;utm_medium=ingest">Brent crude</a>, oil's international benchmark, jumped 1.5%, to $49.55 per barrel, at intraday highs.<a href="https://markets.businessinsider.com/commodities/gold-price">Gold</a> fell as much as 2.4%, to $1,825.81 per ounce.Read more: <a href="https://www.businessinsider.com/investing-strategy-hedge-fund-managers-trades-bets-2020-emmet-peppers-2020-12" target="_blank" rel="noopener">Emmet Peppers grew his accounts from $30,000 in 2010 to over $70 million this year. The newly minted hedge fund manager breaks down how he spotted early opportunities in Tesla, Facebook, and the COVID-19 market crash - and shared one IPO on his radar.</a>

You Searched For "supriya lifescience ipo stock debut" and got 11 results

Supriya Lifescience beats IPO investors expectations and debuts with 55% premium

Bhakti Makwana

Supriya Lifescience, Paras Defence, Indian Hotels, ONGC, and other hot stocks to watch on December 28

Rounak Jain

Supriya Lifescience IPO: Here’s how you can check the allotment status

Bhakti Makwana

Analysts suggest subscribing to this pharma company IPO on discounted valuation and strong product portfolio than peers

Bhakti Makwana

IPOs in FY23 have been fewer but many have fared better than the previous year

Rounak Jain

Nykaa, Policybazaar, Paytm among nine companies whose IPO lock-in period ends in November

Rounak

Bhakti

MFs add HDFC, Reliance Industries, KFin Tech, Sula Vineyards in December

Bhakti Makwana

Adani Wilmar IPO: Here’s how you can check the allotment status

Bhakti Makwana

Ajanta Pharma surges as much as 7% after the drug maker says it will buy back shares at 17% premium

Bhakti Makwana

Sensex surges 500 points; shares of Eicher Motors, L&T, Asian Paints, automobile, IT companies among top gainers

PTI

US stocks retreat from record highs as stimulus deadlock continues

Matthew Fox

Popular Keywords

Buying Guides